| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10512612 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10292939 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10500162 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10568841 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10449159 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10512613 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10507186 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10292938 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10688060 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US9974752 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10111839 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10722473 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Nov, 2038
(14 years from now) | |
Adhansia Xr is owned by Purdue Pharma Lp.
Adhansia Xr contains Methylphenidate Hydrochloride.
Adhansia Xr has a total of 12 drug patents out of which 0 drug patents have expired.
Adhansia Xr was authorised for market use on 27 February, 2019.
Adhansia Xr is available in capsule, extended release;oral dosage forms.
Adhansia Xr can be used as method of treating attention deficit hyperactivity disorder (adhd).
The generics of Adhansia Xr are possible to be released after 19 November, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-82) | Jun 28, 2024 |
| New Product(NP) | Feb 27, 2022 |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 February, 2019
Treatment: Method of treating attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
ADHANSIA XR family patents
